Galapagos is planning to launch a Phase 2 clinical trial for its treatment candidate GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF). Expected to begin in the second half of 2018, the PINTA trial will evaluate the safety and effectiveness of this investigational therapy at several clinical sites in…
Galapagos Announces New Phase 2 Trial Evaluating GLPG1205 in IPF Patients
It is natural for people to experience highs and lows throughout their lives. Significant highs may include milestone events such as marriage, a baby’s birth, or retirement. The death of a loved one, loss of a job, or a relationship breakdown are some examples of the lows we…
Pulmonary fibrosis (PF) and other lung diseases may be late complications in patients with Type 2 diabetes, according to a German study. The study, “Breathlessness and Restrictive Lung Disease: An Important Diabetes-Related Feature in Patients with Type 2 Diabetes,” was published in the journal Respiration. Breathlessness…
NuMedii will collaborate with researchers at Yale School of Medicine and Brigham and Women’s Hospital to develop precision therapies and biomarkers for idiopathic pulmonary fibrosis (IPF). Under this strategic research collaboration, the company will work with teams of two leading experts in interstitial lung disease: Naftali Kaminski, MD, a…
It is human nature to try and relate to one another, especially in times of difficulty. So, when a patient living with pulmonary fibrosis (PF) is having a tough time, it is natural for others to try and relate to our experience. Despite knowing that others intend to…
Blood-Oxygen Levels of IPF Patient Sustained for Over 1 Year Using ECMO, Doctors in Japan Report
A man with idiopathic pulmonary fibrosis (IPF) was kept alive and his blood oxygenated for more than a year while waiting for a lung transplant using a type of extracorporeal membrane oxygenation (ECMO) called veno-venous ECMO — a procedure usually limited in use to about two weeks, researchers in Japan report. They estimate that one…
I’ve been writing this column for almost two years, and it has been a delight to share with you, get to know you, and learn from your wisdom. I write from my experience as a PF patient and share my struggles as well as some tips I’ve learned…
Astragaloside IV — a compound isolated from a traditional Chinese medicinal plant — was found to reverse epithelial–mesenchymal transition, a process crucial to the progression of fibrosis, through its impact on a protein called FOXO3a, a study by researchers in China reports. The study, “Astragaloside IV modulates TGF-b1-dependent epithelial-mesenchymal…
The introduction of bias in the design and analysis of studies likely explains a reported reduction of mortality with antacid therapy in patients with idiopathic pulmonary fibrosis (IPF), according to a new Canadian review study. The research, “The effect of anti-acid therapy on survival in idiopathic…
Since my 2016 IPF diagnosis, so much has changed for me. I can no longer participate in the sports I once enjoyed or go for a run to channel my energy or frustrations with the day. I can no longer maintain the social schedule I was so fond…
Your PF Community
Recent Posts
- Starting the year with a vision of wellness and a plan to follow through January 15, 2026
- New trial data show oral therapy alters immune pathways in adults with IPF January 14, 2026
- When you’re an IPF patient, the costs of care add up, but help is out there January 13, 2026
- Appearances can be deceptive for those living with pulmonary fibrosis January 13, 2026
- Gut bacteria B. adolescentis may be new preventive treatment for PF January 7, 2026
